{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,7]],"date-time":"2026-08-07T14:26:48Z","timestamp":1786112808626,"version":"build-2736575974"},"reference-count":104,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T00:00:00Z","timestamp":1777593600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T00:00:00Z","timestamp":1777593600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,3,12]],"date-time":"2026-03-12T00:00:00Z","timestamp":1773273600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Drug Discovery Today"],"published-print":{"date-parts":[[2026,5]]},"DOI":"10.1016\/j.drudis.2026.104644","type":"journal-article","created":{"date-parts":[[2026,3,16]],"date-time":"2026-03-16T07:31:44Z","timestamp":1773646304000},"page":"104644","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["Deciphering the missing links between Friedreich ataxia and multiple sclerosis for targeted drug development"],"prefix":"10.1016","volume":"31","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-9702-0563","authenticated-orcid":false,"given":"Faith A.A.","family":"Kwa","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sara","family":"Anjomani-Virmouni","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zenouska","family":"Ramchunder","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Evie","family":"Kendal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Junhua","family":"Xiao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.drudis.2026.104644_b0005","doi-asserted-by":"crossref","first-page":"151","DOI":"10.2217\/bmm-2016-0242","article-title":"miRNAs as biomarkers of neurodegenerative disorders","volume":"11","author":"Viswambharan","year":"2017","journal-title":"Biomark Med"},{"key":"10.1016\/j.drudis.2026.104644_b0010","doi-asserted-by":"crossref","first-page":"17","DOI":"10.3389\/fgene.2021.749792","article-title":"Transcriptional analysis of nuclear-encoded mitochondrial genes in eight neurodegenerative disorders: the analysis of seven diseases in reference to Friedreich's ataxia","volume":"12","author":"Elsadany","year":"2021","journal-title":"Front Genet"},{"key":"10.1016\/j.drudis.2026.104644_b0015","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1002\/bies.202300176","article-title":"Emerging small molecule inhibitors of Bach1 as therapeutic agents: rationale, recent advances, and future perspectives","volume":"46","author":"Hushpulian","year":"2024","journal-title":"Bioessays"},{"key":"10.1016\/j.drudis.2026.104644_b0020","doi-asserted-by":"crossref","first-page":"19173","DOI":"10.1038\/s41598-022-23666-z","article-title":"Prediction of the disease course in Friedreich ataxia","volume":"12","author":"Hohenfeld","year":"2022","journal-title":"Sci Rep"},{"key":"10.1016\/j.drudis.2026.104644_b0025","doi-asserted-by":"crossref","first-page":"1816","DOI":"10.1177\/1352458520970841","article-title":"Rising prevalence of multiple sclerosis worldwide: insights from the Atlas of MS, third edition","volume":"26","author":"Walton","year":"2020","journal-title":"Mult Scler"},{"key":"10.1016\/j.drudis.2026.104644_b0030","first-page":"14","article-title":"Multiple sclerosis: 2024 update","volume":"6","author":"Klotz","year":"2025","journal-title":"Free Neuropathol"},{"key":"10.1016\/j.drudis.2026.104644_b0035","doi-asserted-by":"crossref","DOI":"10.1016\/j.nbd.2019.104606","article-title":"Friedreich ataxia: pathogenesis and implications for therapies","volume":"132","author":"Delatycki","year":"2019","journal-title":"Neurobiol Dis"},{"key":"10.1016\/j.drudis.2026.104644_b0040","doi-asserted-by":"crossref","first-page":"174","DOI":"10.1016\/S1474-4422(14)70321-7","article-title":"Biological and clinical characteristics of the European Friedreich's Ataxia Consortium for Translational Studies (EFACTS) cohort: a cross-sectional analysis of baseline data","volume":"14","author":"Reetz","year":"2015","journal-title":"Lancet Neurol"},{"key":"10.1016\/j.drudis.2026.104644_b0045","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1016\/j.jns.2011.05.023","article-title":"Mortality in Friedreich ataxia","volume":"307","author":"Tsou","year":"2011","journal-title":"J Neurol Sci"},{"key":"10.1016\/j.drudis.2026.104644_b0050","doi-asserted-by":"crossref","first-page":"866","DOI":"10.1016\/j.drudis.2021.11.003","article-title":"Molecular approaches for the treatment and prevention of Friedreich's ataxia","volume":"27","author":"Yang","year":"2022","journal-title":"Drug Discov Today"},{"key":"10.1016\/j.drudis.2026.104644_b0055","doi-asserted-by":"crossref","first-page":"725","DOI":"10.1007\/s40265-023-01874-9","article-title":"First approval","volume":"83","author":"Omaveloxolone","year":"2023","journal-title":"Drugs"},{"key":"10.1016\/j.drudis.2026.104644_b0060","unstructured":"Omaveloxolone Early Compassionate Access Program Now Open in Australia! www.fara.org.au\/news\/omaveloxolone-early-compassionate-access-program-now-open-in-australia [Accessed March 10, 2026]."},{"key":"10.1016\/j.drudis.2026.104644_b0065","doi-asserted-by":"crossref","first-page":"188","DOI":"10.3389\/fncel.2018.00188","article-title":"Novel Nrf2-inducer prevents mitochondrial defects and oxidative stress in Friedreich's ataxia models","volume":"12","author":"Abeti","year":"2018","journal-title":"Front Cell Neurosci"},{"key":"10.1016\/j.drudis.2026.104644_b0070","doi-asserted-by":"crossref","first-page":"313","DOI":"10.1002\/mds.29286","article-title":"Efficacy of omaveloxolone in Friedreich's ataxia: delayed-start analysis of the MOXIe Extension","volume":"38","author":"Lynch","year":"2023","journal-title":"Mov Disord"},{"key":"10.1016\/j.drudis.2026.104644_b0075","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1080\/13543784.2023.2173063","article-title":"Omaveloxolone: an activator of Nrf2 for the treatment of Friedreich ataxia","volume":"32","author":"Profeta","year":"2023","journal-title":"Expert Opin Investig Drugs"},{"key":"10.1016\/j.drudis.2026.104644_b0080","unstructured":"Omaveloxolone (Brand Name: SKYCLARYS for >16yo). www.curefa.org\/drug-development\/skyclarys-omaveloxolone\/ [Accessed March 10, 2026]."},{"key":"10.1016\/j.drudis.2026.104644_b0085","doi-asserted-by":"crossref","first-page":"3954","DOI":"10.1093\/hmg\/ddaa282","article-title":"Dimethyl fumarate dose-dependently increases mitochondrial gene expression and function in muscle and brain of Friedreich\u2019s ataxia model mice","volume":"29","author":"Hui","year":"2021","journal-title":"Hum Mol Genet"},{"key":"10.1016\/j.drudis.2026.104644_b0090","doi-asserted-by":"crossref","DOI":"10.3389\/fnins.2023.1260977","article-title":"Rationale and protocol of a double-blind, randomIZed, placebo-controlled trial to test the efficacy, safety, and tolerability of dimethyl fumarate in Friedreich Ataxia (DMF-FA-201)","volume":"17","author":"Pane","year":"2023","journal-title":"Front Neurosci"},{"key":"10.1016\/j.drudis.2026.104644_b0095","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0217776","article-title":"Dimethyl fumarate dosing in humans increases frataxin expression: a potential therapy for Friedreich's Ataxia","volume":"14","author":"Jasoliya","year":"2019","journal-title":"PLoS One"},{"key":"10.1016\/j.drudis.2026.104644_b0100","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0153574","article-title":"Lymphoblast oxidative stress genes as potential biomarkers of disease severity and drug effect in Friedreich's ataxia","volume":"11","author":"Hayashi","year":"2016","journal-title":"PLoS One"},{"key":"10.1016\/j.drudis.2026.104644_b0105","doi-asserted-by":"crossref","first-page":"S683","DOI":"10.33549\/physiolres.934712","article-title":"Coenzyme Q10 effects in neurological diseases","volume":"70","author":"Rauchov\u00e1","year":"2021","journal-title":"Physiol Res"},{"key":"10.1016\/j.drudis.2026.104644_b0110","doi-asserted-by":"crossref","first-page":"1371","DOI":"10.1111\/j.1468-1331.2008.02318.x","article-title":"Coenzyme Q10 and vitamin E deficiency in Friedreich\u2019s ataxia: predictor of efficacy of vitamin E and coenzyme Q10 therapy","volume":"15","author":"Cooper","year":"2008","journal-title":"Eur J Neurol"},{"key":"10.1016\/j.drudis.2026.104644_b0115","doi-asserted-by":"crossref","first-page":"621","DOI":"10.1001\/archneur.62.4.621","article-title":"Antioxidant treatment of patients with Friedreich ataxia: four-year follow-up","volume":"62","author":"Hart","year":"2005","journal-title":"Arch Neurol"},{"key":"10.1016\/j.drudis.2026.104644_b0120","doi-asserted-by":"crossref","first-page":"2197","DOI":"10.1007\/s00210-021-02161-8","article-title":"Coenzyme Q10 a mitochondrial restorer for various brain disorders","volume":"394","author":"Pradhan","year":"2021","journal-title":"Naunyn-Schmiedebergs Arch Pharmacol"},{"key":"10.1016\/j.drudis.2026.104644_b0125","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1007\/s10735-020-09929-x","article-title":"Coenzyme Q10 enhances remyelination and regulate inflammation effects of cuprizone in corpus callosum of chronic model of multiple sclerosis","volume":"52","author":"Khalilian","year":"2021","journal-title":"J Mol Histol"},{"key":"10.1016\/j.drudis.2026.104644_b0130","doi-asserted-by":"crossref","DOI":"10.1177\/1756286418819074","article-title":"Coenzyme Q10 supplementation reduces peripheral oxidative stress and inflammation in interferon-\u03b21a-treated multiple sclerosis","volume":"12","author":"Moccia","year":"2019","journal-title":"Ther Adv Neurol Disord"},{"key":"10.1016\/j.drudis.2026.104644_b0135","doi-asserted-by":"crossref","first-page":"453","DOI":"10.1186\/s13023-025-03990-z","article-title":"Alpha-lipoic acid supplementation improves pathological alterations in cellular models of Friedreich ataxia","volume":"20","author":"Talaver\u00f3n-Rey","year":"2025","journal-title":"Orphanet J Rare Dis"},{"key":"10.1016\/j.drudis.2026.104644_b0140","doi-asserted-by":"crossref","DOI":"10.1212\/WNL.0000000000214454","article-title":"Lipoic acid for treatment of progressive multiple sclerosis","volume":"106","author":"Spain","year":"2026","journal-title":"Neurology"},{"key":"10.1016\/j.drudis.2026.104644_b0145","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1016\/j.jtemb.2016.03.010","article-title":"Iron chelation in the treatment of neurodegenerative diseases","volume":"38","author":"Dusek","year":"2016","journal-title":"J Trace Elem Med Biol"},{"key":"10.1016\/j.drudis.2026.104644_b0150","doi-asserted-by":"crossref","first-page":"530","DOI":"10.1016\/j.nicl.2017.11.003","article-title":"Iron-related gene variants and brain iron in multiple sclerosis and healthy individuals","volume":"17","author":"Hagemeier","year":"2018","journal-title":"Neuroimage Clin"},{"key":"10.1016\/j.drudis.2026.104644_b0155","doi-asserted-by":"crossref","first-page":"715","DOI":"10.1007\/s00210-024-03314-1","article-title":"Deferiprone promoted remyelination and functional recovery through enhancement of oligodendrogenesis in experimental demyelination animal model","volume":"398","author":"Rayatpour","year":"2025","journal-title":"Naunyn Schmiedebergs Arch Pharmacol"},{"key":"10.1016\/j.drudis.2026.104644_b0160","doi-asserted-by":"crossref","first-page":"1796","DOI":"10.1016\/j.intimp.2011.07.007","article-title":"Deferiprone modulates in vitro responses by peripheral blood T cells from control and relapsing-remitting multiple sclerosis subjects","volume":"11","author":"Sweeney","year":"2011","journal-title":"Int Immunopharmacol"},{"key":"10.1016\/j.drudis.2026.104644_b0165","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1182\/blood-2006-12-065433","article-title":"Selective iron chelation in Friedreich ataxia: biologic and clinical implications","volume":"110","author":"Boddaert","year":"2007","journal-title":"Blood"},{"key":"10.1016\/j.drudis.2026.104644_b0170","doi-asserted-by":"crossref","first-page":"509","DOI":"10.1002\/ana.24248","article-title":"Deferiprone in Friedreich ataxia: a 6-month randomized controlled trial","volume":"76","author":"Pandolfo","year":"2014","journal-title":"Ann Neurol"},{"key":"10.1016\/j.drudis.2026.104644_b0175","doi-asserted-by":"crossref","first-page":"1036","DOI":"10.1177\/0883073816636087","article-title":"Clinical experience with deferiprone treatment for Friedreich ataxia","volume":"31","author":"Elincx-Benizri","year":"2016","journal-title":"J Child Neurol"},{"key":"10.1016\/j.drudis.2026.104644_b0180","doi-asserted-by":"crossref","first-page":"964","DOI":"10.1016\/j.ijcard.2015.11.101","article-title":"Efficient attenuation of Friedreich's ataxia (FRDA) cardiomyopathy by modulation of iron homeostasis-human induced pluripotent stem cell (hiPSC) as a drug screening platform for FRDA","volume":"203","author":"Lee","year":"2016","journal-title":"Int J Cardiol"},{"key":"10.1016\/j.drudis.2026.104644_b0185","doi-asserted-by":"crossref","first-page":"2265","DOI":"10.1093\/hmg\/ddn127","article-title":"Iron-dependent regulation of frataxin expression: implications for treatment of Friedreich ataxia","volume":"17","author":"Li","year":"2008","journal-title":"Hum Mol Genet"},{"key":"10.1016\/j.drudis.2026.104644_b0190","doi-asserted-by":"crossref","first-page":"274","DOI":"10.1016\/j.gene.2013.02.049","article-title":"Deferiprone and idebenone rescue frataxin depletion phenotypes in a Drosophila model of Friedreich's ataxia","volume":"521","author":"Soriano","year":"2013","journal-title":"Gene"},{"key":"10.1016\/j.drudis.2026.104644_b0195","doi-asserted-by":"crossref","first-page":"1073","DOI":"10.1007\/s10529-020-02886-1","article-title":"Therapeutic potential of stem cells for treatment of neurodegenerative diseases","volume":"42","author":"Ahmadian-Moghadam","year":"2020","journal-title":"Biotechnol Lett"},{"key":"10.1016\/j.drudis.2026.104644_b0200","doi-asserted-by":"crossref","first-page":"779","DOI":"10.1002\/ana.25207","article-title":"Bone marrow transplantation stimulates neural repair in Friedreich's ataxia mice","volume":"83","author":"Kemp","year":"2018","journal-title":"Ann Neurol"},{"key":"10.1016\/j.drudis.2026.104644_b0205","first-page":"130","article-title":"Mesenchymal stem cells improve motor functions and decrease neurodegeneration in ataxic mice","volume":"23","author":"Jones","year":"2015","journal-title":"MolTher"},{"key":"10.1016\/j.drudis.2026.104644_b0210","doi-asserted-by":"crossref","first-page":"122","DOI":"10.1016\/j.brainres.2011.05.055","article-title":"Human umbilical mesenchymal stem cells enhance the expression of neurotrophic factors and protect ataxic mice","volume":"1402","author":"Zhang","year":"2011","journal-title":"Brain Res"},{"key":"10.1016\/j.drudis.2026.104644_b0215","article-title":"Dietary and lifestyle interventions for the management of hereditary ataxias","volume":"12","author":"Yang","year":"2025","journal-title":"Front Nutr"},{"key":"10.1016\/j.drudis.2026.104644_b0220","doi-asserted-by":"crossref","first-page":"2170","DOI":"10.1007\/s00415-016-8244-7","article-title":"Long-term treatment with thiamine as possible medical therapy for Friedreich ataxia","volume":"263","author":"Costantini","year":"2016","journal-title":"J Neurol"},{"key":"10.1016\/j.drudis.2026.104644_b0225","doi-asserted-by":"crossref","first-page":"504","DOI":"10.1016\/S0140-6736(14)60382-2","article-title":"Epigenetic and neurological effects and safety of high-dose nicotinamide in patients with Friedreich's ataxia: an exploratory, open-label, dose-escalation study","volume":"384","author":"Libri","year":"2014","journal-title":"Lancet"},{"key":"10.1016\/j.drudis.2026.104644_b0230","doi-asserted-by":"crossref","first-page":"7256","DOI":"10.1167\/iovs.14-15193","article-title":"Epigenetic modifications of Keap1 regulate its interaction with the protective factor Nrf2 in the development of diabetic retinopathy","volume":"55","author":"Mishra","year":"2014","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"10.1016\/j.drudis.2026.104644_b0235","series-title":"Health Economic Impact of Multiple Sclerosis in Australia in 2021: an Interim Update of Prevalence, costs and cost of Illness from 2017 to 2021","author":"Campbell","year":"2023"},{"key":"10.1016\/j.drudis.2026.104644_b0240","doi-asserted-by":"crossref","first-page":"545","DOI":"10.1038\/nri3871","article-title":"Immunopathology of multiple sclerosis","volume":"15","author":"Dendrou","year":"2015","journal-title":"Nat Rev Immunol"},{"key":"10.1016\/j.drudis.2026.104644_b0245","doi-asserted-by":"crossref","first-page":"1883","DOI":"10.1056\/NEJMoa2415988","article-title":"Tolebrutinib in nonrelapsing secondary progressive multiple sclerosis","volume":"392","author":"Fox","year":"2025","journal-title":"N Engl J Med"},{"key":"10.1016\/j.drudis.2026.104644_b0250","doi-asserted-by":"crossref","DOI":"10.1016\/j.neurot.2025.e00602","article-title":"Beyond relapses: how BTK inhibitors are shaping the future of progressive MS treatment","volume":"22","author":"Naydovich","year":"2025","journal-title":"Neurotherapeutics"},{"key":"10.1016\/j.drudis.2026.104644_b0255","doi-asserted-by":"crossref","first-page":"1464","DOI":"10.1093\/brain\/awn080","article-title":"Remyelination protects axons from demyelination-associated axon degeneration","volume":"131","author":"Irvine","year":"2008","journal-title":"Brain"},{"key":"10.1016\/j.drudis.2026.104644_b0260","doi-asserted-by":"crossref","first-page":"369","DOI":"10.1111\/j.1750-3639.2005.tb00123.x","article-title":"A 71-year-old male with 4 decades of symptoms referable to both central and peripheral nervous system","volume":"15","author":"Quan","year":"2005","journal-title":"Brain Pathol"},{"key":"10.1016\/j.drudis.2026.104644_b0265","doi-asserted-by":"crossref","DOI":"10.1016\/j.neubiorev.2023.105205","article-title":"Neuropsychiatric symptoms in spinocerebellar ataxias and Friedreich ataxia","volume":"150","author":"Karamazovova","year":"2023","journal-title":"Neurosci Biobehav Rev"},{"key":"10.1016\/j.drudis.2026.104644_b0270","doi-asserted-by":"crossref","first-page":"125","DOI":"10.31887\/DCNS.2007.9.2\/mpucak","article-title":"Neuropsychiatric manifestations of depression in multiple sclerosis: neuroinflammatory, neuroendocrine, and neurotrophic mechanisms in the pathogenesis of immune-mediated depression","volume":"9","author":"Pucak","year":"2007","journal-title":"Dialogues Clin Neurosci"},{"key":"10.1016\/j.drudis.2026.104644_b0275","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1016\/S1474-4422(22)00289-7","article-title":"Multiple sclerosis progression: time for a new mechanism-driven framework","volume":"22","author":"Kuhlmann","year":"2023","journal-title":"Lancet Neurol"},{"key":"10.1016\/j.drudis.2026.104644_b0280","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1056\/NEJMoa0909494","article-title":"A placebo-controlled trial of oral fingolimod in relapsing multiple sclerosis","volume":"362","author":"Kappos","year":"2010","journal-title":"N Engl J Med"},{"key":"10.1016\/j.drudis.2026.104644_b0285","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1177\/1352458516649037","article-title":"Long-term effects of delayed-release dimethyl fumarate in multiple sclerosis: Interim analysis of ENDORSE, a randomized extension study","volume":"23","author":"Gold","year":"2017","journal-title":"Mult Scler"},{"key":"10.1016\/j.drudis.2026.104644_b0290","doi-asserted-by":"crossref","first-page":"1098","DOI":"10.1056\/NEJMoa1114287","article-title":"Placebo-controlled phase 3 study of oral BG-12 for relapsing multiple sclerosis","volume":"367","author":"Gold","year":"2012","journal-title":"N Engl J Med"},{"key":"10.1016\/j.drudis.2026.104644_b0295","doi-asserted-by":"crossref","first-page":"449","DOI":"10.1126\/science.aan4665","article-title":"Dimethyl fumarate targets GAPDH and aerobic glycolysis to modulate immunity","volume":"360","author":"Kornberg","year":"2018","journal-title":"Science"},{"key":"10.1016\/j.drudis.2026.104644_b0300","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1093\/bmb\/ldx034","article-title":"Friedreich's ataxia: clinical features, pathogenesis and management","volume":"124","author":"Cook","year":"2017","journal-title":"Br Med Bull"},{"key":"10.1016\/j.drudis.2026.104644_b0305","article-title":"Inflammatory and interferon gene expression signatures in patients with mitochondrial disease","author":"Warren","year":"2023","journal-title":"Res Sq"},{"key":"10.1016\/j.drudis.2026.104644_b0310","doi-asserted-by":"crossref","first-page":"4278","DOI":"10.1109\/TNSRE.2023.3321874","article-title":"Disease delineation for multiple sclerosis, Friedreich ataxia, and healthy controls using supervised machine learning on speech acoustics","volume":"31","author":"Schultz","year":"2023","journal-title":"IEEE Trans Neural Syst Rehabil Eng"},{"key":"10.1016\/j.drudis.2026.104644_b0315","doi-asserted-by":"crossref","DOI":"10.7554\/eLife.20732","article-title":"Loss of Frataxin activates the iron\/sphingolipid\/PDK1\/Mef2 pathway in mammals","volume":"5","author":"Chen","year":"2016","journal-title":"Elife"},{"key":"10.1016\/j.drudis.2026.104644_b0320","doi-asserted-by":"crossref","DOI":"10.7554\/eLife.16043","article-title":"Loss of Frataxin induces iron toxicity, sphingolipid synthesis, and Pdk1\/Mef2 activation, leading to neurodegeneration","volume":"5","author":"Chen","year":"2016","journal-title":"Elife"},{"key":"10.1016\/j.drudis.2026.104644_b0325","doi-asserted-by":"crossref","DOI":"10.3389\/fphar.2024.1359618","article-title":"Emerging antioxidant therapies in Friedreich's ataxia","volume":"15","author":"Edzeamey","year":"2024","journal-title":"Front Pharmacol"},{"key":"10.1016\/j.drudis.2026.104644_b0330","doi-asserted-by":"crossref","first-page":"339","DOI":"10.2147\/TCRM.S85099","article-title":"Dimethyl fumarate in the management of multiple sclerosis: appropriate patient selection and special considerations","volume":"12","author":"Prosperini","year":"2016","journal-title":"Ther Clin Risk Manag"},{"key":"10.1016\/j.drudis.2026.104644_b0335","unstructured":"Modulation of Frataxin Controlled Metabolic Pathways: Dimethyl Fumarate. www.curefa.org\/drug-development\/dimethyl-fumarate-and-imf\/ [Accessed March 10, 2026]."},{"key":"10.1016\/j.drudis.2026.104644_b0340","doi-asserted-by":"crossref","DOI":"10.1042\/NS20180060","article-title":"Role of frataxin protein deficiency and metabolic dysfunction in Friedreich ataxia, an autosomal recessive mitochondrial disease","volume":"2","author":"Clark","year":"2018","journal-title":"Neuronal Signal"},{"key":"10.1016\/j.drudis.2026.104644_b0345","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1038\/s41582-021-00581-x","article-title":"Mechanism-based criteria to improve therapeutic outcomes in progressive multiple sclerosis","volume":"18","author":"Yong","year":"2022","journal-title":"Nat Rev Neurol"},{"key":"10.1016\/j.drudis.2026.104644_b0350","doi-asserted-by":"crossref","first-page":"14","DOI":"10.3390\/biomedicines7010014","article-title":"Mechanisms of neurodegeneration and axonal dysfunction in progressive multiple sclerosis","volume":"7","author":"Correale","year":"2019","journal-title":"Biomedicines"},{"key":"10.1016\/j.drudis.2026.104644_b0355","doi-asserted-by":"crossref","first-page":"8644","DOI":"10.1523\/JNEUROSCI.2264-20.2021","article-title":"Critical role of astrocyte NAD(+) glycohydrolase in myelin injury and regeneration","volume":"41","author":"Langley","year":"2021","journal-title":"J Neurosci"},{"key":"10.1016\/j.drudis.2026.104644_b0360","doi-asserted-by":"crossref","DOI":"10.1172\/jci.insight.177152","article-title":"NAD+ precursors prolong survival and improve cardiac phenotypes in a mouse model of Friedreich's Ataxia","volume":"9","author":"Perry","year":"2024","journal-title":"JCI Insight"},{"key":"10.1016\/j.drudis.2026.104644_b0365","doi-asserted-by":"crossref","DOI":"10.1016\/j.phrs.2020.104680","article-title":"The potential of the novel NAD(+) supplementing agent, SNH6, as a therapeutic strategy for the treatment of Friedreich's ataxia","volume":"155","author":"Chiang","year":"2020","journal-title":"Pharmacol Res"},{"key":"10.1016\/j.drudis.2026.104644_b0370","doi-asserted-by":"crossref","first-page":"2452","DOI":"10.1093\/hmg\/ddp183","article-title":"Functional genomic analysis of frataxin deficiency reveals tissue-specific alterations and identifies the PPARgamma pathway as a therapeutic target in Friedreich's ataxia","volume":"18","author":"Coppola","year":"2009","journal-title":"Hum Mol Genet"},{"key":"10.1016\/j.drudis.2026.104644_b0375","doi-asserted-by":"crossref","first-page":"268","DOI":"10.1007\/s12264-023-01114-w","article-title":"Peroxisome proliferator-activated receptor-\u03b3 coactivator-1\u03b1 in the spotlight with multiple sclerosis","volume":"40","author":"Yang","year":"2024","journal-title":"Neurosci Bull"},{"key":"10.1016\/j.drudis.2026.104644_b0380","doi-asserted-by":"crossref","DOI":"10.1016\/j.nbd.2020.105162","article-title":"PPAR gamma agonist leriglitazone improves frataxin-loss impairments in cellular and animal models of Friedreich ataxia","volume":"148","author":"Rodr\u00edguez-Pascau","year":"2021","journal-title":"Neurobiol Dis"},{"key":"10.1016\/j.drudis.2026.104644_b0385","doi-asserted-by":"crossref","first-page":"506","DOI":"10.1016\/j.bbadis.2015.09.018","article-title":"Oxidative stress and its impact on neurons and glia in multiple sclerosis lesions","volume":"1862","author":"Lassmann","year":"2016","journal-title":"Biochim Biophys Acta"},{"key":"10.1016\/j.drudis.2026.104644_b0390","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1016\/j.expneurol.2015.11.010","article-title":"Oxidative stress in multiple sclerosis: central and peripheral mode of action","volume":"277","author":"Ohl","year":"2016","journal-title":"Exp Neurol"},{"key":"10.1016\/j.drudis.2026.104644_b0395","doi-asserted-by":"crossref","first-page":"398","DOI":"10.1016\/j.redox.2013.06.004","article-title":"into the role of oxidative stress in the pathology of Friedreich ataxia using peroxidation resistant polyunsaturated fatty acids","volume":"1","author":"Cotticelli","year":"2013","journal-title":"Redox Biol"},{"key":"10.1016\/j.drudis.2026.104644_b0400","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejphar.2020.172973","article-title":"Targeting Keap1\/Nrf2\/ARE signaling pathway in multiple sclerosis","volume":"873","author":"Michali\u010dkov\u00e1","year":"2020","journal-title":"Eur J Pharmacol"},{"key":"10.1016\/j.drudis.2026.104644_b0405","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0004253","article-title":"Impaired nuclear Nrf2 translocation undermines the oxidative stress response in Friedreich ataxia","volume":"4","author":"Paupe","year":"2009","journal-title":"PLoS One"},{"key":"10.1016\/j.drudis.2026.104644_b0410","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1002\/acn3.660","article-title":"Safety, pharmacodynamics, and potential benefit of omaveloxolone in Friedreich ataxia","volume":"6","author":"Lynch","year":"2019","journal-title":"Ann Clin Transl Neurol"},{"key":"10.1016\/j.drudis.2026.104644_b0415","doi-asserted-by":"crossref","first-page":"1507","DOI":"10.4103\/1673-5374.237109","article-title":"Role of nuclear factor \u03baB in multiple sclerosis and experimental autoimmune encephalomyelitis","volume":"13","author":"Yue","year":"2018","journal-title":"Neural Regen Res"},{"key":"10.1016\/j.drudis.2026.104644_b0420","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1177\/1352458510384010","article-title":"Lower levels of glutathione in the brains of secondary progressive multiple sclerosis patients measured by 1H magnetic resonance chemical shift imaging at 3T","volume":"17","author":"Choi","year":"2011","journal-title":"Mult Scler"},{"key":"10.1016\/j.drudis.2026.104644_b0425","doi-asserted-by":"crossref","first-page":"1481","DOI":"10.1089\/ars.2012.4537","article-title":"Frataxin deficiency leads to defects in expression of antioxidants and Nrf2 expression in dorsal root ganglia of the Friedreich's ataxia YG8R mouse model","volume":"19","author":"Shan","year":"2013","journal-title":"Antioxid Redox Signal"},{"key":"10.1016\/j.drudis.2026.104644_b0430","doi-asserted-by":"crossref","first-page":"6289","DOI":"10.3390\/ijms25126289","article-title":"Oxidative stress markers in multiple sclerosis","volume":"25","author":"Jim\u00e9nez-Jim\u00e9nez","year":"2024","journal-title":"Int J Mol Sci"},{"key":"10.1016\/j.drudis.2026.104644_b0435","doi-asserted-by":"crossref","first-page":"1406","DOI":"10.3390\/cells14181406","article-title":"Oxidative stress and antioxidant therapies in Friedreich's ataxia","volume":"14","author":"Jim\u00e9nez-Jim\u00e9nez","year":"2025","journal-title":"Cells"},{"key":"10.1016\/j.drudis.2026.104644_b0440","doi-asserted-by":"crossref","first-page":"198","DOI":"10.1016\/S1474-4422(18)30451-4","article-title":"Association between pathological and MRI findings in multiple sclerosis","volume":"18","author":"Filippi","year":"2019","journal-title":"Lancet Neurol"},{"key":"10.1016\/j.drudis.2026.104644_b0445","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1007\/s00401-016-1636-z","article-title":"Slow expansion of multiple sclerosis iron rim lesions: pathology and 7T magnetic resonance imaging","volume":"133","author":"Dal-Bianco","year":"2017","journal-title":"Acta Neuropathol"},{"key":"10.1016\/j.drudis.2026.104644_b0450","doi-asserted-by":"crossref","first-page":"75","DOI":"10.55782\/ane-2025-2680","article-title":"Iron in multiple sclerosis - from pathophysiology to disease progression - a narrative literature review","volume":"85","author":"K\u0142odnicka","year":"2025","journal-title":"Acta Neurobiol Exp (Wars)"},{"key":"10.1016\/j.drudis.2026.104644_b0455","article-title":"Identification of an iron-responsive subtype in two children diagnosed with relapsing-remitting multiple sclerosis using whole exome sequencing","volume":"19","author":"van Rensburg","year":"2019","journal-title":"Mol Genet Metab Rep"},{"key":"10.1016\/j.drudis.2026.104644_b0460","doi-asserted-by":"crossref","first-page":"4","DOI":"10.31083\/j.jin2301004","article-title":"Tissue iron in Friedreich ataxia","volume":"23","author":"Koeppen","year":"2024","journal-title":"J Integr Neurosci"},{"key":"10.1016\/j.drudis.2026.104644_b0465","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1016\/j.expneurol.2014.02.006","article-title":"Molecular mechanisms linking neuroinflammation and neurodegeneration in MS","volume":"262","author":"Ellwardt","year":"2014","journal-title":"Exp Neurol"},{"key":"10.1016\/j.drudis.2026.104644_b0470","doi-asserted-by":"crossref","first-page":"6297","DOI":"10.3390\/ijms23116297","article-title":"Neuroinflammation in Friedreich's ataxia","volume":"23","author":"Apolloni","year":"2022","journal-title":"Int J Mol Sci"},{"key":"10.1016\/j.drudis.2026.104644_b0475","doi-asserted-by":"crossref","first-page":"6838","DOI":"10.1093\/hmg\/ddu407","article-title":"Frataxin deficiency increases cyclooxygenase 2 and prostaglandins in cell and animal models of Friedreich's ataxia","volume":"23","author":"Hayashi","year":"2014","journal-title":"Hum Mol Genet"},{"key":"10.1016\/j.drudis.2026.104644_b0480","doi-asserted-by":"crossref","first-page":"198","DOI":"10.1186\/s13023-020-01475-9","article-title":"Onset features and time to diagnosis in Friedreich's Ataxia","volume":"15","author":"Indelicato","year":"2020","journal-title":"Orphanet J Rare Dis"},{"key":"10.1016\/j.drudis.2026.104644_b0485","unstructured":"Reference missing."},{"key":"10.1016\/j.drudis.2026.104644_b0490","doi-asserted-by":"crossref","DOI":"10.3389\/fneur.2021.693017","article-title":"Early high efficacy treatment in multiple sclerosis is the best predictor of future disease activity over 1 and 2 years in a Norwegian population-based registry","volume":"12","author":"Simonsen","year":"2021","journal-title":"Front Neurol"},{"key":"10.1016\/j.drudis.2026.104644_b0495","doi-asserted-by":"crossref","first-page":"1437","DOI":"10.1177\/13524585231197076","article-title":"Diagnostic delay of multiple sclerosis: prevalence, determinants and consequences","volume":"29","author":"Uher","year":"2023","journal-title":"Mult Scler"},{"key":"10.1016\/j.drudis.2026.104644_b0500","doi-asserted-by":"crossref","first-page":"522","DOI":"10.1177\/1352458519881558","article-title":"A roadmap to precision medicine for multiple sclerosis","volume":"26","author":"Chitnis","year":"2020","journal-title":"Mult Scler"},{"key":"10.1016\/j.drudis.2026.104644_b0505","series-title":"Omaveloxolone (Skyclarys): Indication: for the Treatment of Friedreich\u2019s Ataxia in Patients 16 Years of Age and Older: Reimbursement Recommendation","author":"Anon.","year":"2025"},{"key":"10.1016\/j.drudis.2026.104644_b0510","doi-asserted-by":"crossref","DOI":"10.1016\/j.neuropharm.2021.108586","article-title":"Current controversies in medical cannabis: recent developments in human clinical applications and potential therapeutics","volume":"191","author":"Schlag","year":"2021","journal-title":"Neuropharmacology"},{"key":"10.1016\/j.drudis.2026.104644_b0515","doi-asserted-by":"crossref","DOI":"10.1016\/j.jaim.2024.100911","article-title":"Assessing effects of cannabis on various neuropathologies: a systematic review","volume":"15","author":"Pathak","year":"2024","journal-title":"J Ayurveda Integr Med"},{"key":"10.1016\/j.drudis.2026.104644_b0520","doi-asserted-by":"crossref","first-page":"443","DOI":"10.1517\/14740338.4.3.443","article-title":"The safety of cannabinoids for the treatment of multiple sclerosis","volume":"4","author":"Smith","year":"2005","journal-title":"Expert Opin Drug Saf"}],"container-title":["Drug Discovery Today"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1359644626000498?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1359644626000498?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,8,5]],"date-time":"2026-08-05T16:20:17Z","timestamp":1785946817000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1359644626000498"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5]]},"references-count":104,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2026,5]]}},"alternative-id":["S1359644626000498"],"URL":"https:\/\/doi.org\/10.1016\/j.drudis.2026.104644","relation":{},"ISSN":["1359-6446"],"issn-type":[{"value":"1359-6446","type":"print"}],"subject":[],"published":{"date-parts":[[2026,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Deciphering the missing links between Friedreich ataxia and multiple sclerosis for targeted drug development","name":"articletitle","label":"Article Title"},{"value":"Drug Discovery Today","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.drudis.2026.104644","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Author(s). Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}],"article-number":"104644"}}